MedTrace Logo

Single and Multiple Ascending Dose Study of V158866 in Healthy Volunteers

NCT01634529 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2012-07-11

No results posted yet for this study

Summary

The purpose of this study is to investigate whether V158866 is safe when given to healthy male subjects in single and multiple doses.

Conditions

  • First in Man Study

Interventions

DRUG

V158866

Single ascending oral doses of V158866 and Placebo

DRUG

V158866

Multiple ascending oral doses of V158866 and Placebo

Sponsors & Collaborators

  • Vernalis (R&D) Ltd

    lead INDUSTRY

Principal Investigators

  • Steve Warrington, MD · Hammersmith Medicines Research Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-07-31
Completion
2011-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01634529 on ClinicalTrials.gov